BIT:1BMY - Euronext Milan - US1101221083 - Common Stock - Currency: EUR
BIT:1BMY (3/3/2025, 7:00:00 PM)
56.73
+1.91 (+3.48%)
The current stock price of 1BMY.MI is 56.73 EUR.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
PFE.DE | PFIZER INC | 8.69 | 140.81B |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Company Website: https://www.bms.com/
Investor Relations: https://www.bms.com/investors.html
Phone: 16092524621
The current stock price of 1BMY.MI is 56.73 EUR. The price increased by 3.48% in the last trading session.
The exchange symbol of BRISTOL-MYERS SQUIBB CO is 1BMY and it is listed on the Euronext Milan exchange.
1BMY.MI stock is listed on the Euronext Milan exchange.
31 analysts have analysed 1BMY.MI and the average price target is 55.91 EUR. This implies a price decrease of -1.44% is expected in the next year compared to the current price of 56.73. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a market capitalization of 115.12B EUR. This makes 1BMY.MI a Large Cap stock.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) currently has 34100 employees.
The Revenue of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is expected to decline by -4.64% in the next year. Check the estimates tab for more information on the 1BMY.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 4.12%. The yearly dividend amount is currently 2.22. Check the full fundamental report for a detailed analysis of 1BMY.MI dividend history, reliability and sustainability.
BRISTOL-MYERS SQUIBB CO (1BMY.MI) will report earnings on 2025-04-24, before the market open.
The PE ratio for BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 54.03. This is based on the reported non-GAAP earnings per share of 1.05 and the current share price of 56.73 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BMY.MI.
ChartMill assigns a technical rating of 3 / 10 to 1BMY.MI.
ChartMill assigns a fundamental rating of 4 / 10 to 1BMY.MI. 1BMY.MI has an average financial health and profitability rating.
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 1.05. The EPS decreased by -84.8% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9.66% | ||
ROE | -54.78% | ||
Debt/Equity | 2.93 |
ChartMill assigns a Buy % Consensus number of 68% to 1BMY.MI. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 498.05% and a revenue growth -4.64% for 1BMY.MI